Testing patients with non-specific symptoms for antibodies against Borrelia burgdorferi sensu lato does not provide useful clinical information about their aetiology  by Markowicz, M. et al.
ORIGINAL ARTICLE INFECTIOUS DISEASESTesting patients with non-speciﬁc symptoms for antibodies against Borrelia
burgdorferi sensu lato does not provide useful clinical information about
their aetiologyM. Markowicz1, D. Kivaranovic2 and G. Stanek1
1) Institute for Hygiene and Applied Immunology and 2) Centre for Medical Statistics, Informatics and Intelligent Systems, Section for Medical Statistics, Medical
University of Vienna, Vienna, AustriaAbstractThe aim of this study was to determine whether patients with antibodies against Borrelia burgdorferi sensu lato or who report a history of
erythema migrans (EM) or tick bite are more likely to have non-speciﬁc symptoms such as musculoskeletal pain, fatigue, sensory
disorder, and headache. The study group comprised 423 subjects with non-speciﬁc symptoms tested for antibodies against B. burgdorferi
sensu lato between July 2012 and December 2014 because of suspicion of Lyme borreliosis (LB). Of these, 285 were females (67%) and
138 were males (33%); the median age was 53 years (range, 7–89 years). Patients with a conﬁrmed diagnosis of LB and patients with a
known underlying disease that could inﬂuence the development of the symptoms were excluded from the evaluation. Subjects were
assigned to the seronegative group or to one of three seropositive groups, and the history of EM and tick bite was also recorded.
Statistical analysis was performed with single chi-square tests of independence and multiple logistic regression models. No differences in
the occurrence of non-speciﬁc symptoms were observed between patients grouped according to antibody status. A history of EM
showed no signiﬁcant effect on any of the non-speciﬁc symptoms. A history of tick bite was weakly correlated with joint pain and joint
swelling (p <0.05). In conclusion, it is highly unlikely that the complaints are related to a previous infection with B. burgdorferi sensu lato.
The results show that testing patients with non-speciﬁc symptoms for antibodies against B. burgdorferi sensu lato in the everyday clinical
setting does not provide any useful information about their aetiology.
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E-mail: mateusz.markowicz@meduniwien.ac.atIntroductionLyme borreliosis (LB) is a tick-borne disease caused by certain
species of tick-borne spirochetes of the Borrelia burgdorferi
sensu lato complex. The disease is characterized by a well-
known clinical course, effective antibiotic treatment, andMicrobiol Infect 2015; 21: 1098–1103
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.08.005laboratory testing that is highly sensitive in the later stages of
the disease [1,2]. Nevertheless, in public discourse, LB is often
presented in the opposite way, and so-called ‘chronic Lyme
disease’ has become a widely used term in connection with
unexplainable clinical conditions potentially leading to disability
or even to life-threatening outcomes, even if the aetiological
role of infection with B. burgdorferi sensu lato is not proven
[3–5]. Long-lasting and repetitive antibiotic treatment is widely
used, despite the risks and lack of efﬁcacy [6].
The aim of this study was to determine whether patients
who have antibodies against B. burgdorferi sensu lato or who
report a history of erythema migrans (EM) are more likely to
have non-speciﬁc symptoms, including musculoskeletal pain,ious Diseases. Published by Elsevier Ltd. All rights reserved
CMIMarkowicz et al. Testing patients with non-speciﬁc symptoms for antibodies against Borrelia burgdorferi sensu lato 1099fatigue, sensory disorder, and headache. The detection of an-
tibodies in serum and a history of EM were used as a surrogate
parameter for previous infection with B. burgdorferi sensu lato.
The data of a high number of individuals were statistically
analysed. Previous tick bites were also evaluated for a possible
role in this respect. The study was approved by the ethical
committee of the Medical University of Vienna.Patients and methodsThe retrospective selection of the study population is shown in
Fig. 1. In total, 705 patients were tested for antibodies against
B. burgdorferi sensu lato between 1 July 2012 and 31 December
2014 at the Institute for Hygiene and Applied Immunology,
Medical University of Vienna. The centre offers consultations
combined with laboratory diagnosis to patients with suspicion
of LB or those with inconclusive antibody results. Patients were
referred by other physicians or were self-referred. All were
seen by the same physician. Each visit was documented with
special respect to symptoms, history of physician-diagnosed EM,
including treatment, and history of tick bite. Other known
diseases were also assessed. Serological testing included an
ELISA for IgG and IgM (Borrelia-ELISA; Medac, Hamburg, Ger-
many) and an immunoblot (Anti-Borrelia Euroline Westernblot;
Euroimmun, Lübeck, Germany) for conﬁrmation of borderline
and positive ELISA results. The tests were performed according
to the manufacturers’ instructions.705
serologically tested
01.07.2012 to 31.12.2014
43
proven LB
45
underlying
disease
617
423
non-specific symptoms
meeƟng inclusion criteria
194 
asymptomaƟc or other symptoms
not meeƟng inclusion criteria
FIG. 1. Flow chart showing selection of the study population.
A detailed explanation is given in ‘Patients and methods’.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology anForty-three patients with proven LB at presentation were
excluded from further evaluation: 22 patients with EM, two
with multiple EM, ﬁve with acrodermatitis chronica atrophi-
cans, three with Lyme neuroborreliosis (LNB) conﬁrmed by
cerebrospinal ﬂuid pleocytosis and a positive cerebrospinal
ﬂuid/serum antibody index, and ﬁve with Lyme arthritis; six
patients who had been diagnosed with LNB in the past were
also excluded. Forty-ﬁve patients presented with a known un-
derlying disease that could have an inﬂuence on the symptoms,
and these patients were also excluded from the evaluation.
Eight of them suffered from a neurological disease, including
multiple sclerosis, Parkinson’s disease, myasthenia gravis, and a
history of hydrocephalus, nine had a diagnosis of diabetes
mellitus, nine had spinal disk herniations or other arthritic ab-
normalities of the spine, ten had a diagnosed neoplasm, and 11
had other known diseases unrelated to LB. Two patients suf-
fered from more than one disease at the same time.
One hundred and ninety four patients without any symptoms
or with symptoms which did not meet inclusion criteria were
also excluded. Finally, 423 subjects with the following symptoms
were included in the evaluation: joint pain (divided into three
minor categories: pain in one large joint, pain in several joints,
and pain in only small joints, predominantly the wrists and ﬁn-
gers), joint swelling, muscle pain or muscle cramp, back pain,
fatigue, forgetfulness, sensory disorder, headache, visual disor-
der, and vertigo. These symptoms were considered to be
possible consequences of LB. Each patient who reported at least
one of these symptoms was tested for antibodies and included in
the study. If additional symptoms were present, they were
classiﬁed as ‘others’. This category was not used for statistical
analysis. Individuals who only had symptoms in this category
were not included in the study population, as mentioned above.
If patients were retested during the study period, only the
ﬁrst visit was considered.
On the basis of the ELISA results, each of the 423 patients
was assigned to one of three seropositive groups (IgG positive/
IgM positive, IgG positive/IgM negative, and IgG negative/IgM
positive) or to the seronegative group. The single-tier criterion
was adopted deliberately for assignment in order to assess a
‘worst-case scenario’. The immunoblot was performed
routinely for all positive ELISA results, and it conﬁrmed
approximately 90% of all positive IgG ELISA results and
approximately 78% of all positive IgM ELISA results. These
proportions did not change between the individual groups.
Therefore, we could expect that applying a two-tier criterion
would not inﬂuence the results.
Descriptive statistics were calculated for baseline parame-
ters for the total patient sample. Continuous variables were
described as median and range, and categorical variables as
absolute values and percentages.d Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1098–1103
1100 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMISingle chi-square tests of independence were performed to
compare the rates of the non-speciﬁc symptoms among the
four serological categories. Ninety-ﬁve per cent proﬁle CIs
were calculated for the individual rates, and are shown in Fig. 2.
The multiple analysis of the non-speciﬁc symptoms was based
on logistic regression models with history of EM and history of
tick bite. In addition, we adjusted for age as a confounder. The
estimated ORs were tested for signiﬁcance with z-tests.
p-Values of 0.05 were considered to be statistically signif-
icant. All calculations were performed with R 3.0.2.ResultsIn total, 138 (33%) males and 285 (67%) females were included.
The median age was 53 years (range, 7–89 years). The de-
mographic details for each antibody category, including history
of EM and tick bite, are shown in Table 1.
Three hundred and twenty-four (77%) patients could specify
the duration of their symptoms. The median duration of
symptoms was 40 weeks, ranging from 1 week to 30 years. In
211 (65%) patients, the duration of symptoms was <1 year.
Table 2 shows the frequencies of non-speciﬁc symptoms for
each serological category. The results of the univariate logistic
regressions are shown in Fig. 2. The null hypothesis of inde-
pendence could not be rejected for any of the non-speciﬁc
symptoms. All p-values of the chi-squared tests were above
the signiﬁcance level of 0.05. The percentage of non-speciﬁc
symptoms did not signiﬁcantly differ between the seropositive
groups and the seronegative controls. Despite the large sample
size, the CIs showed a widely overlap, which is evidence that
the non-speciﬁc symptoms were unrelated to the serological
status.FIG. 2. Impact of antibody status on non-speciﬁc symptoms; 95% CIs of the
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectPrevious EM was reported by 104 (24%) patients, namely 30
(29%) men and 74 (71%) women. Two hundred and twenty-
three (53%) patients reported previous tick bite, namely 77
(35%) males and 146 (65%) females. Comparisons of the fre-
quency of non-speciﬁc symptoms between patients with and
without a history of EM and tick bite are shown in Table 3.
Multivariate analysis of history of EM showed no signiﬁcant
effect on any of the non-speciﬁc symptoms. History of tick bite
was a weakly signiﬁcant predictor for joint pain and for joint
swelling (p< 0.05).
The exact time interval between the EM and the onset of
symptoms was known for 64 (15%) patients. Seven patients
reported EM twice. In these cases, the time point of the ﬁrst EM
was used. The median time interval was 37 weeks, ranging from
0 weeks to 25 years. In 15 (23%) patients, the non-speciﬁc
symptoms started simultaneously with the appearance of the
rash, 19 (30%) patients reported the onset of symptoms within
1 year after EM, and in the remaining 30 (47%) patients the non-
speciﬁc symptoms began after 1 year.DiscussionSerological testing for antibodies against B. burgdorferi sensu lato
is a cornerstone of the laboratory diagnosis of LB [7]. The
highest sensitivity is achieved in the late stage of the disease.
However, antibodies can be detected for years in healthy in-
dividuals [8,9], even after an asymptomatic infection. The
widespread use of serological testing in patients who do not
meet the clinical criteria for LB [7] can lead to incorrect diag-
nosis of the disease, especially if no other reasons for the
complaints can be found [10–12]. Many of the patients included
in this study had visited different specialists and undergone apercentages.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1098–1103
TABLE 1. Demographic data of the study population, including history of erythema migrans (EM) and tick bite
Sex (absolute
frequency (%))
Total (absolute
frequency (%))
Age (years)
History of EM (absolute
frequency (%))
History of tick bite (absolute
frequency (%))Male Female Median Minimum Maximum
IgG negative
IgM negative
63 (30) 147 (70) 210 (100) 48 7 86 36 (17) 102 (49)
IgG positive
IgM positive
21 (38) 34 (62) 55 (100) 56 9 76 21 (38) 34 (61)
IgG positive
IgM negative
35 (39) 55 (61) 90 (100) 54 23 89 18 (20) 54 (60)
IgG negative
IgM positive
19 (28) 49 (72) 68 (100) 53 8 77 29 (43) 33 (49)
Total 138 (33) 285 (67) 423 (100) — — — 104 (24) 223 (53)
CMIMarkowicz et al. Testing patients with non-speciﬁc symptoms for antibodies against Borrelia burgdorferi sensu lato 1101variety of investigations in order to ﬁnd the reasons for their
complaints.
In the present analysis, the possible inﬂuence of previous
infection with B. burgdorferi sensu lato on non-speciﬁc com-
plaints was investigated. First, the outcomes of seropositive and
seronegative subjects were compared. Seroprevalence can be
considered as a reliable surrogate parameter for previous
infection with the pathogen. In the second step, patients who
reported physician-diagnosed EM were compared with patients
without a history of EM. A possible inﬂuence of infection with
B. burgdorferi sensu lato on the development of non-speciﬁc
complaints is described by the so-called ‘post-Lyme disease
syndrome’ (PLDS) [13–15], which includes fatigue and muscu-
loskeletal pain, symptoms that were assessed in the present
study. The syndrome is valid only for patients with a docu-
mented history of early or late LB after treatment according to
recommendations. Patients with a history of EM in the present
study correspond, to some extent, with the deﬁnition of PLDS.
All participants were asked about previous EM that had been
diagnosed by a physician and treated accordingly [1].
The evidence for the aetiology of PLDS is not well estab-
lished. Similar symptoms occur in the general populationTABLE 2. Non-speciﬁc symptoms; comparison between antibody c
Joint pain
Joint
swelling
Muscle
pain/muscle
cramp Back pain
One large
joint
Several
joints
Small
joints
IgG negative
IgM negative
n = 210
17 (8) 92 (44) 10 (5) 16 (8) 65 (31) 22 (9)
IgG positive
IgM positive
n = 55
5 (9) 24 (43) 2 (4) 4 (7) 16 (29) 3 (5)
IgG positive
IgM negative
n = 90
4 (4) 43 (48) 6 (7) 5 (6) 23 (26) 13 (14)
IgG negative
IgM positive
n = 68
9 (6) 33 (49) 5 (7) 2 (3) 28 (42) 5 (7)
Total
n = 423
35 (8) 192 (45) 19 (4) 27 (6) 132 (31) 43 (10)
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology anwithout a history of LB, which is the major limitation in the
investigation of its possible causality [11,12]. The infectious
cause of the complaints could not be assessed; identiﬁcation of
a pathogen in patients with non-speciﬁc symptoms after anti-
biotic treatment for LB was not possible. Animal models have
shown that antibiotic treatment is highly efﬁcient in clearing the
pathogen from the tissue [16]. The post-infectious effect on the
immune response without persistence of the pathogen is a
current topic of discussion and focus of research [17,18].
Finally, antibiotic treatment was not found to be beneﬁcial for
those patients in controlled trials [6,19]. On the other hand,
evaluation of the antibody proﬁle in PLDS patients from the
USA showed different reactivities to several speciﬁc proteins of
B. burgdorferi sensu lato than in a control population [15]. This
ﬁnding strengthens the role of the immunological response in
this respect.
Different genospecies of B. burgdorferi sensu lato cause
different clinical manifestations in Europe, whereas, in North
America, B. burgdorferi sensu stricto is the only agent of LB.
Even if a history of LB could be associated with the develop-
ment of some non-speciﬁc symptoms in patients in the USA, it
would not necessarily apply to Europe. The majority of studiesategories (absolute frequency (%))
Fatigue Forgetfulness
Sensory
disorder Headache
Visual
disorder Vertigo Other
48 (23) 1 (0) 29 (14) 27 (13) 7 (3) 14 (7) 53 (25)
11 (20) 1 (2) 8 (14) 10 (18) 2 (4) 1 (2) 10 (18)
21 (23) 1 (1) 14 (16) 11 (12) 4 (4) 2 (2) 9 (10)
14 (21) 1 (1) 7 (10) 8 (12) 3 (4) 2 (3) 13 (19)
94 (22) 4 (1) 58 (14) 56 (13) 16 (4) 19 (4) 85 (20)
d Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1098–1103
TABLE 3. Non-speciﬁc symptoms; comparison between patients with and without a history of erythema migrans (EM), and with
and without a history of tick bite (absolute frequency (%))
Joint pain
Joint
swelling
Muscle
pain/muscle
cramp
Back
pain Fatigue Forgetfulness
Sensory
disorder Headache
Visual
disorder Vertigo Other
One large
joint
Several
joints
Small
joints
History of EM 11 (11) 45 (43) 6 (6) 4 (4) 41 (39) 10 (10) 19 (18) 1 (1) 11 (11) 11 (11) 3 (3) 1 (1) 14 (13)
No history of EM 21 (7) 147 (46) 17 (5) 23 (7) 91 (29) 33 (10) 75 (24) 3 (1) 47 (15) 45 (14) 13 (4) 18 (6) 71 (22)
History of tick bite 14a (6) 112a (50) 14a (6) 9a (4) 70 (31) 25 (11) 53 (24) 3 (1) 24 (11) 27 (12) 9 (4) 13 (6) 47 (21)
No history tick bite 18a (9) 80a (40) 9a (4) 18a (9) 62 (31) 18 (9) 41 (20) 1 (0) 34 (17) 29 (14) 7 (4) 6 (3) 38 (19)
ap <0.05 (calculated for joint pain as a single category).
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with Lyme disease were treatment trials focusing on outcomes
after different antibiotic regimens [20–23]. In a European
prospective clinical trial, it was shown that the frequency of
non-speciﬁc symptoms in patients treated for EM did not
exceed the frequency of such symptoms in a control group
without a clinical history of LB [24]. Greater severity of
symptoms was found in patients with a history of EM than in
controls; however, greater sensitivity to the symptoms in this
group might explain this ﬁnding. Similar conclusions regarding
EM and non-speciﬁc symptoms can be drawn from present
evaluation. Note that the role of disseminated LB in this respect
has not been analysed.
Surprisingly, a history of tick bite showed a positive corre-
lation with joint pain and joint swelling. To explain this
dependence, one can argue that patients who have symptoms of
unknown origin may be more likely to associate them with a
previous tick bite and to consider them to be a potential
consequence of LB. For this reason, they may pay more
attention to previous tick bites than individuals without symp-
toms. On the other hand, there might be another, unknown,
trigger for the development of the symptoms caused by tick
bites. The present analysis clearly shows that an aetiological
role of borrelial infection is highly improbable in this respect.
The exclusion of asymptomatic patients (Fig. 1) in this study
deserves some explanation. The majority of patients without
symptoms have already shown positive serological test results
in another laboratory. Therefore, the frequency of seropositive
subjects in the asymptomatic group could be overestimated in
relation to the general population. To overcome this problem,
only patients with certain, well-deﬁned symptoms were
included in the evaluation.
Patients with some known underlying diseases were
excluded from the evaluation in order to rule out a possible
overlap between the disease and the potential inﬂuence of LB
on the symptoms. One can argue that this step was arbitrary, as
some chronic diseases do not cause all of the symptoms
investigated in the study. For instance, diabetes mellitus canClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectcause polyneuropathy resulting in sensory disorder, but it is
rather less probable that it can cause joint pain. However, the
total number of such subjects was low as compared with the
total sample size. For instance, there were ﬁve patients with
diabetes and joint pain. Among patients with different neuro-
logical diseases, ﬁve reported muscle pain and two reported
joint pain. The inclusion of these patients in the analysis did not
considerably change the results of the study.
Five patients with a history of proven LNB were not included
in the evaluation. Clinical follow-up of these patients should be
discussed. All were treated with ceftriaxone. The ﬁrst patient
received a diagnosis of LNB twice, 9 years and 2 years previ-
ously. Several painful complaints were reported afterwards;
however, the symptoms could also be explained by verte-
brostenosis, diagnosed with magnetic resonance imaging. Of
the remaining four patients, two reported lumboischialgia 1
year and 10 years after the diagnosis of LNB, respectively.
Another patient, a 12-year-old child, reported ankle pain and
tiredness 7 months after the diagnosis. Because of the small
number of patients and the lack of full diagnostic work-up, it is
difﬁcult to conﬁrm a possible inﬂuence of previous LNB on
these symptoms. The last patient was symptom-free 3 months
after treatment. In three patients who presented with Bann-
warth syndrome, LNB was conﬁrmed with lumbar puncture
later on. All patients presented for follow-up visits, and all of
them were symptom-free after 4 months, 1 year, and 2 years,
respectively.
Some limitations of the study should be mentioned. Although
patients with known underlying diseases were excluded from
the evaluation, some of the participants might have had other
unknown diseases [25,26]. The majority of patients had been
seen by other specialists, and no deﬁnitive diagnosis had been
made; thus, a diagnosis of LB was considered to be possible. It
should be noted that seropositivity and anamnestic EM were
used as surrogate parameters for the previous infection.
However, patients with an early stage of the disease or who
have received early treatment may not develop speciﬁc anti-
bodies. Furthermore, not all patients recall EM or tick bites.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1098–1103
CMIMarkowicz et al. Testing patients with non-speciﬁc symptoms for antibodies against Borrelia burgdorferi sensu lato 1103Finally, patients with disseminated LB regardless of antibody
status could not be included in the present study design.ConclusionsThe results show that testing patients with non-speciﬁc symp-
toms for antibodies against B. burgdorferi sensu lato in the
everyday clinical setting does not provide any useful informa-
tion about their aetiology. An aetiological role of B. burgdorferi
sensu lato in the development of self-reported complaints in
seropositive patients and in patients with history of EM is rather
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